About
Team
Pipeline
OPN-2853
OPN-6602
OPN-FMRP
OPN-7486
OPN-9840
OPN-9627
Patients
News
Press Releases
Publications
& Posters
Careers
Contact
General information
info@opnabio.com
Investor inquiries
bd@opnabio.com
Media and BD inquiries
bd@opnabio.com
OPN-6602
Select PROGRAMS
All Programs
OPN-2853
(8)
OPN-51107
(17)
OPN-6602
(2)
OPN-7486
(5)
OPN-TEAD
(1)
Select Dates
All Dates
2024
(2)
2023
(3)
2022
(1)
2021
(3)
2020
(3)
2019
(7)
2018
(4)
2017
(3)
2016
(2)
2015
(3)
April 7, 2024
Poster
OPN-6602, a potent dual EP300/CBP bromodomain inhibitor, targets multiple myeloma through concomitant suppression of IRF4 and c-MYC
AUTHORS
Matusow, et al
Programs
OPN-6602
Download PDF
October 14, 2023
Poster
OPN-6602, a dual EP300/CBP bromodomain inhibitor modulates androgen-driven transcription in mCRPC
AUTHORS
Matusow, et al
Programs
OPN-6602
Download PDF